Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy - Summary - MDSpire

Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

  • By

  • Jeongin Yoo

  • Dong Ho Lee

  • Do-Youn Oh

  • Jeesun Yoon

  • Sang Hyub Lee

  • In Rae Cho

  • Woo Hyun Paik

  • May 28, 2026

  • 0 min

Share

Objective:

To evaluate the potential role of immune-related adverse events (irAEs) detected on imaging studies in predicting prognosis in biliary tract cancer (BTC) patients treated with a combination of durvalumab plus gemcitabine and cisplatin.

Approach:
    Key Findings:
    • Immune-related adverse events may correlate with favorable clinical outcomes, but their relationship with imaging findings in BTC has not been thoroughly investigated. [source needed]
    Interpretation:

    Limitations:
    • The study is retrospective and may have inherent biases.
    • The requirement for written informed consent was waived, which could affect data integrity.
    Conclusion:

Original Source(s)

Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

  • by Jeongin Yoo, Dong Ho Lee, Do-Youn Oh, Jeesun Yoon, Sang Hyub Lee, In Rae Cho, Woo Hyun Paik

  • May 28, 2026

Related Content

PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review

Editorial: Understanding oral health challenges in pediatric and adult cancer care

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma